DeepMed Research

Henan Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1977-01-01

Employees: -

Market Cap: -

Website: http://www.anti-cancer.com.cn

Clinical Trials

GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel

Phase 2

Withdrawn

Conditions: Early Breast Cancer

Interventions: Other: Placebo
Drug: monosialic gangliosides

First Posted Date: 2020-09-04

Last Posted Date: 2022-11-23

Lead Sponsor: Henan Cancer Hospital

Registration Number: NCT04538833

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Phase 2

Recruiting

Conditions: Marginal Zone Lymphoma

Interventions: Drug: Bortezomib
Drug: Rituximab
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2020-06-16

Last Posted Date: 2023-05-18

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT04433156

Locations: 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy

Phase 2

Conditions: Tumor
Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: 5-HT3 receptor antagonist
Drug: Megestrol
Drug: dexamethasone

First Posted Date: 2020-06-12

Last Posted Date: 2020-06-12

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 120

Registration Number: NCT04430361

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma

Phase 2

Conditions: Gastric and Esophagogastric Junction Adenocarcinoma

Interventions: Drug: PD-1 Monoclonal Antibody(Sintilimab)

First Posted Date: 2020-04-10

Last Posted Date: 2021-08-24

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 25

Registration Number: NCT04341857

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC

Phase 4

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: Gemcitabine Injectable Product

First Posted Date: 2020-04-02

Last Posted Date: 2020-04-02

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 50

Registration Number: NCT04331626

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Pyrotinib
Drug: SHR6390

First Posted Date: 2020-03-03

Last Posted Date: 2023-05-06

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 41

Registration Number: NCT04293276

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Phase 3

Recruiting

Conditions: Esophageal Cancer
Surgery
Neoadjuvant Treatment
Survival

Interventions: Drug: Neoadjuvant immunochemotherapy

First Posted Date: 2020-02-21

Last Posted Date: 2022-10-04

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 400

Registration Number: NCT04280822

Locations: 🇨🇳
Henan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzhou University), Zhengzhou, Henan, China

L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy

Conditions: Advanced Solid Tumor

Interventions: Biological: liquid tumor infiltrating lymphocytes

First Posted Date: 2020-02-13

Last Posted Date: 2020-06-11

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT04268108

Locations: 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China

Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma

Recruiting

Conditions: Gene Abnormality
Lymphoma

First Posted Date: 2020-02-11

Last Posted Date: 2025-04-23

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 200

Registration Number: NCT04263935

Locations: 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Anrotenib plus Toripalimab
Drug: Toripalimab

First Posted Date: 2020-01-18

Last Posted Date: 2020-01-18

Lead Sponsor: Henan Cancer Hospital

Target Recruit Count: 164

Registration Number: NCT04229849

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy